Samalizumab
Samalizumab is a humanized monoclonal antibody designed for oncology indications.[1]
Monoclonal antibody | |
---|---|
Type | Whole antibody |
Source | Humanized (from mouse) |
Target | CD200 |
Clinical data | |
ATC code |
|
Identifiers | |
CAS Number | |
ChemSpider |
|
UNII | |
KEGG | |
Chemical and physical data | |
Formula | C6542H10086N1702O2102S46 |
Molar mass | 147687.22 g·mol−1 |
(what is this?) (verify) |
Samalizumab was developed by Alexion Pharmaceuticals.
References
This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.